Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion

Ovarian cancer is difficult to treat, and the mucinous epithelial subtype has a particularly poor response to traditional chemotherapy regimens. Entrectinib is a tumor-agnostic tyrosine kinase inhibitor with limited data regarding its use in ovarian cancers, though it demonstrates significant tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Olivia G., Hardesty, Melissa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131062/
https://www.ncbi.nlm.nih.gov/pubmed/37122438
http://dx.doi.org/10.1016/j.gore.2023.101187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131062/
https://www.ncbi.nlm.nih.gov/pubmed/37122438
http://dx.doi.org/10.1016/j.gore.2023.101187

Ejemplares similares